Looks like Easton Pharmaceuticals Inc (PINK:EAPH) is determined to gain. Despite losing 20% of its price on Wednesday, 
yesterday the stock got back on track and soared 3.17% on the market.
Actually, that’s been the usual chart movement of EAPH lately. The reasons for its price hesitations are crystal clear – promotions and press releases.
The records show that EAPH has been promoted throughout the whole September by different websites, which pumped up its stock price. Yesterday, the total compensation for the promotions reached $10,000, though the paying parties remained unknown.
Apart form the campaign, Easton released some positive news recently to support its market position. The latest came up just yesterday when the company reported that it has entered into discussions for a distribution agreement in East Asia. However, no agreement has been signed yet. [BANNER]
Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops and markets a premium array of topically-delivered therapeutic healthcare products. A couple of days ago, an attorney letter filed with the SEC confirmed that no person related to Easton was under investigation by any federal or state regulatory authority and the company’s financial statements have not been audited. However, the statements are not satisfying at all.
As recently reported on hotstocked.com, as of June 30 this year, the company had more assets than liabilities in its balance, though its accumulated deficit jumped over $36 million. At the same time, the net loss kept increasing, while revenues totaled $nil.
In other words, Easton is operating under a going concern, while its ability to continue remains questionable.
